Changes in Prescription Drug and Health Care Use Over 9 Years After the Large Drug Price Increase for Colchicine
JAMA Internal Medicine · 2023
DOI: 10.1001/jamainternmed.2023.0898 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, 2023. Verfasst von Dan P Ly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles. Hauptthemen laut MEDLINE: Prescription Drugs, Gout. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Importance Prescription drug prices are a leading concern among patients and policy makers. There have been large and sharp price increases for some drugs, but the long-term implications of large drug price increases remain poorly understood.
Objective
To examine the association of the large 2010 price increase in colchicine, a common treatment for gout, with long-term changes in colchicine use, substitution with other drugs, and health care use. Design, Setting, and Participants This retrospective cohort study examined MarketScan data from a longitudinal cohort of patients with gout with employer-sponsored insurance from 2007 through 2019. Exposures The US Food and Drug Administration’s discontinuation of lower-priced versions of colchicine from the market in 2010. Main Outcomes and Measures Mean price of colchicine; use of colchicine, allopurinol, and oral corticosteroids; and emergency department (ED) and rheumatology visits for gout in year 1 and over the first decade of the policy (through 2019) were calculated. Data were analyzed between November 16, 2021, and January 17, 2023.
Results
A total of 2 723 327 patient-year observations were examined from 2007 through 2019 (mean [SD] age of patients, 57.0 [13.8] years; 20.9% documented as female; 79.1% documented as male). The mean price per prescription of colchicine increased sharply from $11.25 (95% CI, $11.23-$11.28) in 2009 to $190.49 (95% CI, $190.07-$190.91) in 2011, a 15.9-fold increase, with the mean out-of-pocket price increasing 4.4-fold from $7.37 (95% CI, $7.37-$7.38) to $39.49 (95% CI, $39.42-$39.56). At the same time, colchicine use declined from 35.0 (95% CI, 34.6-35.5) to 27.3 (95% CI, 26.9-27.6) pills per patient in year 1 and to 22.6 (95% CI, 22.2-23.0) pills per patient in 2019. Adjusted analyses showed a 16.7% reduction in year 1 and a 27.0% reduction over the decade ( P < .001). Meanwhile, adjusted allopurinol use rose by 7.8 (95% CI, 6.9-8.7) pills per patient in year 1, a 7.6% increase from baseline, and by 33.1 (95% CI, 32.6-33.7) pills per patient through 2019, a 32.0% increase from baseline over the decade ( P < .001). Moreover, adjusted oral corticosteroid use exhibited no significant change in the first year, then increased by 1.5 (95% CI, 1.3-1.7) pills per patient through 2019, an 8.3% increase from baseline over the decade. Adjusted ED visits for gout rose by 0.02 (95% CI, 0.02-0.03) per patient in year 1, a 21.5% increase, and by 0.05 (95% CI, 0.04-0.05) per patient through 2019, a 39.8% increase over the decade ( P < .001). Adjusted rheumatology visits for gout increased by 0.02 (95% CI, 0.02-0.03) per patient through 2019, a 10.5% increase over the decade ( P < .001). Conclusions and Relevance In this cohort study among individuals with gout, the large increase in colchicine prices in 2010 was associated with an immediate decrease in colchicine use that persisted over approximately a decade. Substitution with allopurinol and oral corticosteroids was also evident. Increased ED and rheumatology visits for gout over the same period suggest poorer disease control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles.
- VA Greater Los Angeles Healthcare System, Los Angeles, California.
- Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
- Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
- Center for Primary Care, Harvard Medical School, Boston, Massachusetts.
Förderung
- NIH HHS
- NIA NIH HHS
Zitieren
APA
Ly, D. P., Giuriato, M. A., & Song, Z. (2023). Changes in Prescription Drug and Health Care Use Over 9 Years After the Large Drug Price Increase for Colchicine. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2023.0898
Vancouver
Ly DP, Giuriato MA, Song Z. Changes in Prescription Drug and Health Care Use Over 9 Years After the Large Drug Price Increase for Colchicine. JAMA Internal Medicine. 2023. doi:10.1001/jamainternmed.2023.0898
BibTeX
@article{Ly2023,
author = {Ly, Dan P and Giuriato, Mia A and Song, Zirui},
title = {Changes in Prescription Drug and Health Care Use Over 9 Years After the Large Drug Price Increase for Colchicine},
journal = {JAMA Internal Medicine},
year = {2023},
doi = {10.1001/jamainternmed.2023.0898}
}
EUVIMED